As filed with the Securities and Exchange Commission on April 2, 2019

Registration No. 333-217831

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Post-Effective Amendment No. 1

to

FORM S-8

REGISTRATION STATEMENT NO. 333-217831

UNDER

THE SECURITIES ACT OF 1933

 

 

IMMUNE DESIGN CORP.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware		1616 Eastlake Ave. E., Suite 310 Seattle, Washington 98102 (206) 682-0645		26-2007174
(State or other jurisdiction of incorporation)		(Address of principal executive offices including zip code)		(I.R.S. Employer Identification Number)

Immune Design Corp. 2014 Omnibus Incentive Plan

(Full title of the plan)

 

 

Copies to:

Geralyn Ritter Secretary Immune Design Corp. 1616 Eastlake Ave. E., Suite 310 Seattle, Washington 98102		Barbara L. Becker Saee Muzumdar Gibson, Dunn & Crutcher LLP 200 Park Avenue New York, NY 10166-0193

(Name and address of agent for service)

 

 

(206) 682-0645

(Telephone number, including area code, of agent for service)

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer		☐		Accelerated filer		☒
Non-accelerated filer		☐		Smaller reporting company		☒
				Emerging growth company		☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.  ☒

 

 

 

DEREGISTRATION OF SECURITIES

This Post-Effective Amendment No. 1 relates to the following Registration Statement on Form S-8 (the “Registration Statement”) filed by Immune Design Corp., a Delaware corporation (the “Company”) with the Securities and Exchange Commission:

 

•

Registration No. 333-217831, filed on May 10, 2017, registering 1,016,522 shares of common stock of the Company, $0.001 par value per share, in connection with the Company’s 2014 Omnibus Incentive Plan.

Pursuant to the Agreement and Plan of Merger, dated as of February 20, 2019 (the “Merger Agreement”), by and among the Company, Merck Sharp & Dohme Corp., a New Jersey corporation (the “Parent”) and Cascade Merger Sub Inc., a Delaware corporation and a wholly owned subsidiary of Parent (the “Purchaser”), the Purchaser merged with and into the Company, with the Company continuing as the surviving corporation and a direct wholly owned subsidiary of Parent. As a result of the transactions contemplated by the Merger Agreement, the Company has terminated all offerings of its securities pursuant to the Registration Statement and hereby removes and withdraws from registration all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof. The Registration Statement is hereby amended, as appropriate, to reflect the deregistration of such securities.

 

1

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Kenilworth, in the State of New Jersey, on this 2nd day of April, 2019.

 

Pursuant to the Rule 478 of the Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1 to the Registration Statement.

 

2